GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Poseida Therapeutics Inc (STU:2RZ) » Definitions » Additional Paid-In Capital

Poseida Therapeutics (STU:2RZ) Additional Paid-In Capital : €646.94 Mil(As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Poseida Therapeutics Additional Paid-In Capital?


Poseida Therapeutics's quarterly additional paid-in capital declined from Sep. 2023 (€649.15 Mil) to Dec. 2023 (€639.93 Mil) but then increased from Dec. 2023 (€639.93 Mil) to Mar. 2024 (€646.94 Mil).

Poseida Therapeutics's annual additional paid-in capital increased from Dec. 2021 (€498.31 Mil) to Dec. 2022 (€621.72 Mil) and increased from Dec. 2022 (€621.72 Mil) to Dec. 2023 (€639.93 Mil).


Poseida Therapeutics Additional Paid-In Capital Historical Data

The historical data trend for Poseida Therapeutics's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Poseida Therapeutics Additional Paid-In Capital Chart

Poseida Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Additional Paid-In Capital
Get a 7-Day Free Trial 2.42 447.04 498.31 621.72 639.93

Poseida Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 623.22 620.94 649.15 639.93 646.94

Poseida Therapeutics Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Poseida Therapeutics Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Poseida Therapeutics's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Poseida Therapeutics (STU:2RZ) Business Description

Traded in Other Exchanges
Address
9390 Towne Centre Drive, Suite 200, San Diego, CA, USA, 92121
Poseida Therapeutics Inc is a clinical-stage biopharmaceutical company focused on leveraging non-viral gene engineering technologies to create life-saving therapeutics for patients with a high unmet medical need. It has built a pipeline of autologous and allogeneic chimeric antigen receptor T cell, or CAR-T, product candidates, initially focused on the treatment of hematological malignancies and solid tumours.

Poseida Therapeutics (STU:2RZ) Headlines

No Headlines